

Joint meeting of Coronary Revascularization (JCR2017) in Busan, Korea

# Increased Dipeptidyl Peptidase-4 Accelerates Diet-Related Vascular Aging and Atherosclerosis in ApoE-Deficient Mice under Chronic Stress


Department of ICU  
Yanbian University Hospital


Yanna Lei MD, PhD;  
Xianwu Cheng, MD, PhD, FAH



December 9, 2017

# Stress and Disease







# DPP-4 and its inhibitors



---

⊠ DPP-4 is a complex enzyme that acts as a membrane-anchored cell surface exopeptidase that **truncates a large number of peptides** (e.g., hormones, cytokines, and growth factors). DPP-4 has gained considerable interest as a therapeutic target, and a variety of DPP-4 inhibitors that prolong **the insulinotropic effects of glucagon-like peptide-1 (GLP-1)** are widely used in clinical settings as antidiabetic drugs.


# DPP-4 and it's substrates




# Chronic psychological stress increased blood DPP-4 levels in a time dependent manner



# CAD and ACS patients had increased levels of plasma DPP-4






# Objective

---

⊠ The aim of our study was to investigate the effects of DPP-4 inhibitor on vascular aging and atherosclerotic plaque growth and the related mechanisms with special focusing on **APN-PPAR  $\alpha$**  signaling activation in ApoE<sup>-/-</sup> mice under chronic psychological stress.

**APN**: adiopoectin; **PPAR- $\alpha$** : Peroxisome Proliferator-Activated Receptor;

# Protocol (1)




6-week-old male ApoE<sup>-/-</sup> mice  
(KOR/StmSlc background)

# Effects of stress on plasma lipid profile and DPP4, leptin, GLP-1, and APN levels





Parameter	Non-stress	Stress
T-ch (mg/dL)	575.2 ± 14.3	562.5 ± 15.8
HDL-C (mg/dL)	23.1 ± 2.2	23.0 ± 2.3
Triglyceride (mg/dL)	135.1 ± 4.8	73.5 ± 4.0**
NEFA (μEQ/L)	194 ± 12	106 ± 12**
BUN (mg/dL)	3.9 ± 0.3	4.2 ± 0.3
Creatinine (mg/dL)	0.5 ± 0.0	0.8 ± 0.0
Glucose (mg/dL)	39.3 ± 2.6	36.1 ± 2.9
<b>DPP4 (ng/ L)</b>	<b>305 ± 28</b>	<b>823 ± 34**</b>
<b>Leptin (pg/ml)</b>	<b>402 ± 45</b>	<b>177 ± 25**</b>
<b>GLP-1 (pM)</b>	<b>15.9 ± 1.1</b>	<b>9.2 ± 0.8**</b>
<b>APN (ng/mL)</b>	<b>7577 ± 382</b>	<b>5619 ± 598*</b>

T-ch: total cholesterol; HDL-C: high-density lipoprotein cholesterol; NEFA: nonesterified fatty acid; BUN: blood urine nitrogen; DPP4: dipeptidyl peptidase-4; GLP-1, glucagon like protein-1; APN, adiponectin. Data are mean ± SEM. \*  $P < 0.05$ , \*\*  $P < 0.01$  by ANOVA and Tukey's *post hoc* tests.



# Stress reduced subcutaneous/inguinal adipose and body weight (BW)





# Stress accelerated vascular senescence and plaque lipid accumulation and growth







# Stress reduced plaque collagen volume and promoted elastin degradation




# Stress enhanced mac infiltration, inflammatory chemokine expression and neovessel formation




# Stressed aortas had increased levels of MMP-2/-9, TIMP1/2, CatS/K/L and APN and decreased eNOS genes




# Stress increased levels of AT1R and gp91phox and decreased levels PPAR- $\alpha$ , except p-AMPK proteins



# Protocol (2)









# DPP4 inhibition increased levels of APN and GLP-1 proteins

Parameter	Stress	S-Ana
Triglyceride (mg/dL)	21.1 ± 2.2	13.6 ± 3.1*
LDL (mg/dL)	47.6 ± 6.1	38.1 ± 12.5
HDL (mg/dL)	4.3 ± 0.2	5.0 ± 0.0
NEFA (μEQ/L)	152 ± 8	136 ± 13
BUN (mg/dL)	3.2 ± 0.4	4.1 ± 0.8
Creatinine (mg/dL)	0.5 ± 0.0	0.5 ± 0.0
DPP4 (ng/ L)	976 ± 4	477 ± 22**
Leptin (pg/ml)	214 ± 9	301 ± 25**
GLP-1 (pM)	11.3 ± 0.6	19.4 ± 0.8**
APN (ng/mL)	5574 ± 417	8492 ± 584**


# DPP4 inhibition mitigated vascular aging and plaque growth and collagen/elastin metabolism





# Anagliptin inhibited macrophage infiltration and inflammatory chemokine expression





# DPP4 inhibition mitigates the changes in AT1R, PPAR- $\alpha$ , p-AMPK, and gp91phox proteins



# DPP4 inhibition reduced MMP-2/-9 activity




# GLP-1 analogues exenatide stimulated APN expression in adipocytes in a dose-dependent manner, but not by anagliptin




# GLP-1 analogues exenatide improved atherosclerotic lesion formation


**Stress S-Exe**



**Stress**





**Stress+Exe**



**Oil red O staining**

# Proposed mechanisms





# Conclusion

---

These results indicate that the DPP-4 inhibition-mediated benefits are likely attributable, at least in part, to attenuation the plaque inflammation, oxidative stress and proteolysis associated with GLP-1-mediated APN production in ApoE<sup>-/-</sup> mice under stress. Thus, DPP-4 will be a novel therapeutic target for the treatment of stress-related cardiovascular disease.



Thank You !

谢谢

